[Pharmacological treatment of restenosis after coronary angioplasty and bypass grafting].
Angioplasty and bypass surgery have become standard methods of treating patients with symptomatic coronary atherosclerosis but restenosis remains the major limitation of percutaneous coronary revascularization. In pharmacological management of restenosis after coronary intervention multiple agents have been tried, with mostly discouraging results. Aspirin, dipyridamole, ticlopidine, heparin. Hirudin, and warfarin has failed to show beneficial effects on restenosis. Of all antithrombotics, only an inhibitor of the platelet IIb/IIIa integrin, which may lead to early vessel changes, leading to decrease restenosis. Antiproliferative agent (trapidil and angiopeptin) and probucol have also resulted in improved restenosis rate. In patients after bypass surgery with some degree of hyperlipidemia intensive lipid-lowering therapy is beneficial in slowing the late progressions of atherosclerosis as well as graft occlusion.
Halawa
B
B
Katedry i Kliniki Kardiologii AM we Wrocławiu.
D017130:Angioplasty / Q000379:methods*; D001161:Arteriosclerosis / Q000601:surgery*; D001026:Coronary Artery Bypass / Q000379:methods*; D003327:Coronary Disease / Q000175:diagnosis*; D006801:Humans; D011183:Postoperative Complications / Q000175:diagnosis*; D011475:Prosthesis Failure
Farmakologiczne zapobieganie zwezeniu tetnic po zabiegach przezskórnej plastyki tetnic wieńcowych i ich przesłowaniu.